Maria Baggstrom is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 105 publications with 2,091 citations (h-index 20); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 631101032
Telephone
800-647-2098Registry record last updated 15 Apr 2025.
Clinical trials
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
- 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab
Sponsor: Washington University School of Medicine
- Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
75.5%Other antiemetics64.1%Fosaprepitant100%Part B, office-administered≥14 patientsSerotonin-3 Receptor Antagonist10.3%Palonosetron hcl57%Granisetron hydrochloride38%Ondansetron Hcl5%Part D + Part B≥23 patients+ 2 more classes in this area
Sensory organs
10.6%Corticosteroid10.6%Dexamethasone sodium phosphate92%Dexamethasone8%Part D + Part B≥32 patientsCancer & immunology
7.3%Nucleoside Metabolic Inhibitor7.1%Gemcitabine hydrochloride54%Fluorouracil46%Part B, office-administered≥16 patientsMitogen-activated protein kinase (MEK) inhibitors0.2%Mektovi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Cancer Epidemiology Biomarkers & Prevention
2024 - Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution
Journal of Medical Internet Research
2023 - Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics
2022 - Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology
2022 - A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
Journal of Thoracic Disease
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”